Protagonist Therapeutics, Inc
About Protagonist Therapeutics, Inc
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2017
- $8.8M
- Net income
- -$130.1M
- Total assets
- $668.2M
- Market cap
- $6.3B
- Operating margin
- -343.6%
- Net margin
- -282.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $46.0M
- Operating expenses
- $204.1M
- Operating income
- -$158.1M
- Income tax
- $838.0K
- Net income
- -$130.1M
- EPS (basic)
- $-2.05
- EPS (diluted)
- $-2.05
Balance sheet
- Total assets
- $668.2M
- Current assets
- $577.6M
- Total liabilities
- $53.5M
- Current liabilities
- $45.4M
- Shareholders’ equity
- $614.7M
Cash flow
- Operating cash flow
- $57.7M
- Investing cash flow
- -$49.3M
- Financing cash flow
- $22.9M
- Net cash flow
- $31.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $6.3B
- EPS (diluted)
- $-2.05
- Shares outstanding
- 63.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 11, 2016
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $130.1M in FY2017.
- Revenue grew 61% from FY2020 to FY2025.
- Trading 8% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Protagonist Therapeutics, Inc.
Write a review
News about Protagonist Therapeutics, Inc
News & sentiment via Polygon.io
